BR112014029708A2 - composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina - Google Patents

composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina Download PDF

Info

Publication number
BR112014029708A2
BR112014029708A2 BR112014029708A BR112014029708A BR112014029708A2 BR 112014029708 A2 BR112014029708 A2 BR 112014029708A2 BR 112014029708 A BR112014029708 A BR 112014029708A BR 112014029708 A BR112014029708 A BR 112014029708A BR 112014029708 A2 BR112014029708 A2 BR 112014029708A2
Authority
BR
Brazil
Prior art keywords
pyrrolo
triazine
triazine compound
preparing
compound
Prior art date
Application number
BR112014029708A
Other languages
English (en)
Other versions
BR112014029708A8 (pt
BR112014029708B1 (pt
Inventor
Yang Chunhao
Tan Cun
Ding Jian
Li Jiapeng
Meng Linghua
Wang Xiang
Chen Yanhong
Chen Yi
Original Assignee
Shanghai Haihe Pharmaceutical Co Ltd
Shanghai Inst Materia Medica Cas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Haihe Pharmaceutical Co Ltd, Shanghai Inst Materia Medica Cas filed Critical Shanghai Haihe Pharmaceutical Co Ltd
Publication of BR112014029708A2 publication Critical patent/BR112014029708A2/pt
Publication of BR112014029708A8 publication Critical patent/BR112014029708A8/pt
Publication of BR112014029708B1 publication Critical patent/BR112014029708B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

resumo “composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina” a presente invenção se refere a um composto de pirrolo[2,1-f][1,2,4]triazina, um isômero do mesmo ou um sal, éster ou hidrato farmaceuticamente aceitável do mesmo, e a um método de preparação e aplicação do mesmo. o composto de pirrolo[2,1-f][1,2,4]triazina tem uma estrutura expressa na fórmula geral (i). (i) o composto de pirrolo[2,1-f][1,2,4]triazina expresso na fórmula geral (i) pode inibir uma via de sinalização de fosfatidilinositol-3 quinase (p13k), sendo assim utilizado no preparo de medicamentos para tratar doenças relacionadas com fosfatidilinositol-3 quinase, tal como câncer. 1/1
BR112014029708-8A 2012-05-31 2013-04-23 Composto de pirrolo[2,1-f][1,2,4]triazina e método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina BR112014029708B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210177980.3A CN103450204B (zh) 2012-05-31 2012-05-31 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
CN201210177980.3 2012-05-31
PCT/CN2013/074559 WO2013177983A1 (zh) 2012-05-31 2013-04-23 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途

Publications (3)

Publication Number Publication Date
BR112014029708A2 true BR112014029708A2 (pt) 2017-06-27
BR112014029708A8 BR112014029708A8 (pt) 2021-09-08
BR112014029708B1 BR112014029708B1 (pt) 2023-05-02

Family

ID=49672377

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029708-8A BR112014029708B1 (pt) 2012-05-31 2013-04-23 Composto de pirrolo[2,1-f][1,2,4]triazina e método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina

Country Status (14)

Country Link
US (1) US9447101B2 (pt)
EP (1) EP2857403B1 (pt)
JP (1) JP6067107B2 (pt)
KR (1) KR101824299B1 (pt)
CN (1) CN103450204B (pt)
AU (1) AU2013270326B2 (pt)
BR (1) BR112014029708B1 (pt)
CA (1) CA2874062C (pt)
ES (1) ES2703934T3 (pt)
HK (1) HK1203499A1 (pt)
MX (1) MX359207B (pt)
RU (1) RU2589053C1 (pt)
SG (1) SG11201407752YA (pt)
WO (1) WO2013177983A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724352B2 (en) * 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
US9447105B2 (en) 2013-01-24 2016-09-20 Council Of Scientific & Industrial Research Triazine compounds and a process for preparation thereof
WO2016064958A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
EP3209664B1 (en) 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2018528951A (ja) * 2015-08-31 2018-10-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＴＧＦβ受容体アンタゴニスト
CN109641909B (zh) * 2016-06-25 2022-01-11 苏州开拓药业股份有限公司 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN109111447A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
WO2019034076A1 (zh) * 2017-08-15 2019-02-21 南京明德新药研发股份有限公司 Fgfr抑制剂及其医药用途
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
MX2022003217A (es) * 2019-09-19 2022-06-29 Totus Medicines Inc Conjugados terapeuticos.
CN112851563A (zh) * 2020-12-30 2021-05-28 安徽金鼎医药股份有限公司 N-氨基-3-氮杂双环[3,3,0]辛烷盐酸盐的合成工艺
WO2023035614A1 (zh) * 2021-09-10 2023-03-16 上海海和药物研究开发股份有限公司 包含PI3Kα抑制剂的药物组合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
US7232901B2 (en) 2005-07-01 2007-06-19 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5185930B2 (ja) 2006-07-07 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
AU2007282535B9 (en) * 2006-08-08 2013-06-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as PI3K inhibitor and use thereof
US7888352B2 (en) * 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
US8148522B2 (en) 2007-01-02 2012-04-03 Bristol-Myers Squibb Company Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate
EP2134716A1 (en) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
MX2010004260A (es) * 2007-10-16 2010-04-30 Wyeth Llc Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa.
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
WO2010002954A1 (en) * 2008-07-02 2010-01-07 Wyeth (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US8513284B2 (en) * 2009-02-13 2013-08-20 Ucb Pharma, S.A. Fused pyridine and pyrazine derivatives as kinase inhibitors
CA2756759C (en) * 2009-04-16 2017-11-07 Joaquin Pastor Fernandez Imidazopyrazines for use as kinase inhibitors
WO2011089400A1 (en) * 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
US20130131057A1 (en) * 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
CN102675323B (zh) * 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途

Also Published As

Publication number Publication date
MX2014014622A (es) 2015-08-10
CN103450204A (zh) 2013-12-18
EP2857403A1 (en) 2015-04-08
EP2857403A4 (en) 2015-10-21
HK1203499A1 (en) 2015-10-30
MX359207B (es) 2018-09-19
BR112014029708A8 (pt) 2021-09-08
RU2589053C1 (ru) 2016-07-10
AU2013270326B2 (en) 2016-07-14
BR112014029708B1 (pt) 2023-05-02
CA2874062A1 (en) 2013-12-05
JP6067107B2 (ja) 2017-01-25
SG11201407752YA (en) 2015-01-29
US9447101B2 (en) 2016-09-20
CA2874062C (en) 2015-09-22
JP2015518010A (ja) 2015-06-25
KR101824299B1 (ko) 2018-03-14
ES2703934T3 (es) 2019-03-13
US20150141644A1 (en) 2015-05-21
WO2013177983A1 (zh) 2013-12-05
AU2013270326A1 (en) 2014-12-18
EP2857403B1 (en) 2018-10-10
CN103450204B (zh) 2016-08-17
KR20150009565A (ko) 2015-01-26

Similar Documents

Publication Publication Date Title
BR112014029708A2 (pt) composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina
GB201104267D0 (en) Pyrrolopyridineamino derivatives
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
MX2016003457A (es) Compuestos aminopirimidina sustituidos y metodos de uso.
BR112015015635A8 (pt) composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BR112015015653A8 (pt) composto, método de preparação dos compostos, composto para uso, composição farmacêutica e métodos in vitro
MX2010003668A (es) Derivados de purina sustituidas con primidina.
BR112013014184A2 (pt) compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
CO6690816A2 (es) Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa
PE20150637A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
ECSP13012764A (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA Y SU USO COMO INHIBIDOR DUAL DE CINASA PI3/mTOR
NZ700283A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
AU2009282962A8 (en) Compounds as kinase inhibitors
BR112014002245A2 (pt) derivados de piridin-2(1h)-ona como inibidores de jak
BR112015027440A2 (pt) DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO
IN2015DN01408A (pt)
GB201302704D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25A Requested transfer of rights approved

Owner name: SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN)

B25D Requested change of name of applicant approved

Owner name: HAIHE BIOPHARMA CO., LTD. (CN)

B25G Requested change of headquarter approved

Owner name: HAIHE BIOPHARMA CO., LTD. (CN)